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Putin et al. [1] just published an excellent article 
showing how machine learning methods (specifically 
deep neural networks, DNNs) can be used to quantify 
the aging process using a set of 41 standard clinical 
biomarkers, most of which are not specifically 
recognized as biomarkers of aging. DNNs provide a 
method to obtain a predictive algorithm from raw data 
(the biomarkers in this case) with minimal to no a priori 
assumptions (see Mamoshina et al. 2016 [2] for details). 
This is an important finding because (a) it confirms that 
aging is not a single specific process, but rather a suite 
of changes that are felt across multiple physiological 
systems, probably within a complex systems frame-
work, and (b) it suggests that measurement of the aging 
process is feasible with simple, standard measures. Both 
of these agree with recent findings from our lab 
showing that similar sets of biomarkers perform well for 
measurement of physiological dysregulation [3-7]. The 
difference is that our models are geared toward 
understanding the biology, and Putin et al. [1]’s toward 
prediction (i.e., estimation of biological age, though 
they do not use the term). Their model substantially 
outperforms ours for age prediction, but because the 
underlying algorithm is sufficiently complex as to 
remain a black box, it can provide relatively little 
insight into mechanisms. The two approaches are thus 
complementary. 
There is, however, a substantial caveat to Putin et al. 
[1]’s approach that was not mentioned in their article. 
Their algorithm was developed based on clinical data 
from a single source covering Eastern Europe (90% 
Russia), and the applicability to data from other settings 
or to population subsets was not verified. There are a 
number of reasons to suspect that their algorithm would 
need to be adjusted for application in other settings: (1) 
Aging rates may differ across countries; (2) Genetic and 
environmental determinants of physiology may differ 
across countries/cultures, independent of aging; and (3) 
There may be specific biases in how clinical lab 
samples are taken and analyzed that differ substantially 
across health systems. These distinctions are not trivial: 
a universal measure of biological age has very different 
practical and biological implications than one that is 
highly contextual. They also represent a more general 
challenge for machine learning in the health domain: 
traditional applications  of  such  techniques  (e.g. facial  
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recognition, sentence completion [2]) are not generally 
subject to bias or anything related to the epidemio-
logical concept of confounding, whereas such problems 
are rife in (bio)medical fields. There is thus substantial 
potential for development of methodological 
approaches to adjust for bias in machine learning 
methods applied in biomedical research. 
We have access to similar data  to that used by Putin et 
al. [1] for three major aging cohort studies, the 
Women’s Health and Aging Study I &II (WHAS)[8], 
the Baltimore Longitudinal Study on Aging (BLSA)[9, 
10], and Invecchiare in Chianti (InCHIANTI)[11], as 
well as publicly available cross-sectional data for a 
representative sample of the American population from 
the National Health and Nutrition Examination Survey 
(NHANES)[12]. For each study, we randomly chose 
110 participants, stratified by age when necessary to 
achieve a broad age range, and input their values for the 
10 basic biomarkers (albumin, glucose, alkaline 
phosphatase, urea, erythrocytes, cholesterol, RDW, 
alpha-2 globulins, hematocrit, and lymphocytes) in the 
online tool provided by Putin et al. [1] at www.aging.ai. 
Alpha-2-globulins were only present in InCHIANTI, so 
we left the field empty in the other data sets (the DNN 
is capable of treating missing data, though this reduces 
accuracy). In addition, we ran as many of the full 41 
biomarkers as possible for a set of 10 individuals per 
study, chosen randomly by age stratum from among the 
110 run with 10 biomarkers. The number of biomarkers 
available was: WHAS: 34 biomarkers out of 41, BLSA: 
37, InCHIANTI: 38, and NHANES: 33. 
We found that indeed the performance of the model was 
substantially diminished in all four of our data sets. In 
the original study, the 10-biomarker version of the DNN 
has a 10-year epsilon accuracy (i.e., percentage correct 
prediction within age±10 years) of 70% and R2 = 0.63; 
across our datasets the mean epsilon accuracy was 38% 
and mean R2 = 0.37, with maximum epsilon accuracy = 
56% (InCHIANTI) and maximum R2 = 0.59 (NHANES, 
Fig. 1). The 41-biomarker versions performed neither 
markedly better nor worse, with a mean age error 
(MAE) actually increasing by 0.45 (95%CI: [-2.2, 1.3]) 
across our 40 samples. The confidence intervals and 
consistency across data sets are sufficient to exclude the 
possibility that our core results are due to the use of the 
10-biomarker rather than the 41-biomarker tool (Fig. 1).  
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In addition to heterogeneity of performance across data 
sets, the DNN had a significantly better performance for 
men than for women globally (MAE diff= 1.8, p=0.04) 
and in InCHIANTI (MAE diff= 5.5, p=0.002) and 
NHANES (MAE diff= 4.2, p=0.007), though there was 
no significant effect in BLSA (MAE diff= -1.5, p=0.39). 
This is consistent with our findings on other measures 
of biological age, which for some reason consistently 
perform better for men, even when the methods are 
calibrated on women ([4] and unpublished data using 
methods from [13, 14]). 
One potential reason for the poorer performance of the 
model in our datasets is the absence of children. 
Including children increases the age range, which by 
itself, all else equal, will increase r and R2 statistics [15]. 
Whether a measure of biological age needs to be accurate 
for children too is perhaps debatable or context-
dependent, but clearly we would like the measure to be 
able to discriminate ages among adults well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, we found a clear bias in the age estimates 
for BLSA and WHAS, with age substantially 
underestimated for almost all individuals in both data 
sets (Fig. 1a, b). This is actually consistent with the 
results of Putin et al. [1]. Their Fig. 1 a, d shows a bias 
toward underestimation of age for individuals aged 70+, 
and the BLSA and WHAS datasets largely contain 
individuals in this age range. For InCHIANTI and 
NHANES as well, ages of older individuals are 
underestimated and ages of younger individuals are 
overestimated, though less so than for BLSA and 
WHAS. Globally this suggests that Putin et al. [1]’s 
model performs well when the age range is large, but 
loses discriminatory power particularly at older ages. If 
the age bias is larger in BLSA and WHAS, as it appears 
to be, this might also imply that these populations age 
more slowly, an interesting finding.  
However, such differences could also be due to 
something more mundane such as diet. Dietary patterns 
differ substantially between Eastern Europe, Italy, and 
the US, and diet is known to affect many clinical 
biomarkers (e.g. [16-18] ), so it is hardly surprising that 
performance of algorithms based on these markers differs 
across these populations. Likewise, the majority of data 
used by Putin et al. [1] come from middle-aged 
individuals, and life expectancy in Russia is much lower 
than in Italy or the US [19], and has a substantially 
different cause composition [20]. We expect that many 
such factors contribute jointly to the patterns observed 
here. 
In sum, these results show that there is unlikely to be a 
single algorithm that can predict biological age for all 
populations/sexes based on these clinical biomarkers. 
While we have not explored other population strata, 
such as by race, socioeconomic status, or environmental 
exposures, differences likely exist among these groups 
as well. The methods used by Putin et al. [1] are state of 
the art and perform well within their original dataset, 
suggesting that the barrier is true population differences 
rather than algorithm refinement. Population-specific 
algorithms might be an option but would require 
substantial work. Practically, this result is unfortunate, 
but biologically it is interesting. It implies that aging 
proceeds differently, and perhaps at different rates, in 
different populations. Other measures of biological age – 
for example, the epigenetic clock, or based on highly 
specific aging biomarkers such as leukocyte telomere 
length (LTL) – may or may not face these same hurdles 
[13-15, 21-23]. However, longitudinal changes in LTL 
depend on demographics, genes, and environment [24], 
implying that there will be population differences in how 
it works as a measure of biological age. More broadly, 
our results suggest that substantial caution is warranted in 
generalizing age-related changes in biomarkers across 
populations. Future work should attempt to replicate 
Figure 1. Correlation between actual and predicted age values on
110  observations  from  four  databases  (a)  WHAS,  (b)  BLSA,  (c)
InCHIANTI,  and  (d)  NHANES]  using  the  DNN  on  10  biomarkers
(small  circles)  or  all  available  biomarkers  (large  squares).  Paired
observations with  10  and  all  available  biomarkers  are  linked  by
vertical  lines.  Orange  symbols  are  men  and  black  symbols  are
women.   MAE  is mean age error and ∆ MAE  is difference between
MAE using 10 biomarkers and MAE using all available biomarkers,
with  positive  values  indicating  better  performance  of  the model
with  all  biomarkers.  ∆ MAE  parentheses  indicate  95%  confidence
intervals. 
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these findings in appropriate datasets from non-Western 
countries [25, 26], and to assess the performance of more 
diverse, integrated datasets. 
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